Akero Therapeutics Q4 EPS $(0.99) Down From $(0.49) YoY; Cash, Cash Equivalents, Short-term And Long-term Marketable Securities Of $569.3M Is Will Be Sufficient To Fund The Company's Current Operating Plan Into 2026
Portfolio Pulse from Benzinga Newsdesk
Akero Therapeutics reported a Q4 EPS loss of $(0.99), a 102.04% increase in losses compared to $(0.49) per share YoY. The company has $569.3M in cash and securities, expected to fund operations into 2026.
February 29, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Akero Therapeutics reported a significant increase in quarterly losses but has sufficient cash to fund operations into 2026.
The increased loss may concern investors, but the substantial cash reserves provide a safety net, potentially stabilizing the stock in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100